Phreesia, Inc. (PHR)
NYSE$25.45
Market Cap
$1.48B
Sector
Healthcare
Industry
Medical—Healthcare Information Services
Rank in Sector
777 of 924
Rank in Industry
33 of 40
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PHR Insider Trading Activity
PHR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $13,954,663 | 117 | 100 |
Related Transactions
| Egbuonu-Davis Lisa | director | 0 | $0 | 1 | $32,239 | $-32,239 |
| Hui Yvonne | Principal Accounting Officer | 0 | $0 | 9 | $133,645 | $-133,645 |
| Smith Mark Douglas | director | 0 | $0 | 1 | $175,000 | $-175,000 |
| Gunzburg Janet | Principal Accounting Officer | 0 | $0 | 7 | $200,537 | $-200,537 |
| VanDuyn Amy Beth | SVP, Human Resources | 0 | $0 | 11 | $1.03M | $-1.03M |
| Weintraub Michael | director | 0 | $0 | 4 | $1.32M | $-1.32M |
| Hoffman Allison C | General Counsel & Secretary | 0 | $0 | 15 | $1.79M | $-1.79M |
| Linetsky David | SVP, Life Sciences | 0 | $0 | 28 | $1.84M | $-1.84M |
| Gandhi Balaji | Chief Financial Officer | 0 | $0 | 14 | $1.98M | $-1.98M |
| Indig Chaim | Chief Executive Officer | 0 | $0 | 10 | $2.14M | $-2.14M |
| Roberts Evan | Chief Operating Officer | 0 | $0 | 17 | $3.31M | $-3.31M |
About Phreesia, Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and …
Insider Activity of Phreesia, Inc.
Over the last 12 months, insiders at Phreesia, Inc. have bought $0 and sold $13.95M worth of Phreesia, Inc. stock.
On average, over the past 5 years, insiders at Phreesia, Inc. have bought $0 and sold $29.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Phreesia, Inc.
| 2025-02-19 | Sale | Roberts Evan | Chief Operating Officer | 177 0.0003% | $30.00 | $5,310 | -13.03% | |
| 2025-02-19 | Sale | Gandhi Balaji | Chief Financial Officer | 96 0.0002% | $30.00 | $2,880 | -13.03% | |
| 2025-02-18 | Sale | Roberts Evan | Chief Operating Officer | 3,519 0.0061% | $30.06 | $105,764 | -14.61% | |
| 2025-02-18 | Sale | Hoffman Allison C | General Counsel & Secretary | 3,496 0.006% | $29.72 | $103,901 | -14.61% | |
| 2025-02-18 | Sale | Gandhi Balaji | Chief Financial Officer | 5,771 0.01% | $30.04 | $173,377 | -14.61% | |
| 2025-02-14 | Sale | Roberts Evan | Chief Operating Officer | 3,586 0.0062% | $30.13 | $108,039 | -13.54% | |
| 2025-02-14 | Sale | Gandhi Balaji | Chief Financial Officer | 4,889 0.0084% | $30.09 | $147,089 | -13.54% | |
| 2025-02-13 | Sale | Roberts Evan | Chief Operating Officer | 16,005 0.0291% | $30.00 | $480,152 | -12.86% | |
| 2025-02-13 | Sale | Linetsky David | SVP, Life Sciences | 11,616 0.0209% | $29.70 | $345,001 | -12.86% | |
| 2025-02-13 | Sale | Gandhi Balaji | Chief Financial Officer | 28,759 0.0522% | $30.00 | $862,770 | -12.86% | |
| 2025-02-07 | Sale | Linetsky David | SVP, Life Sciences | 300 0.0005% | $29.52 | $8,857 | -7.56% | |
| 2025-02-05 | Sale | Linetsky David | SVP, Life Sciences | 720 0.0013% | $29.50 | $21,241 | -6.59% | |
| 2025-01-29 | Sale | Linetsky David | SVP, Life Sciences | 500 0.0009% | $29.68 | $14,841 | -2.09% | |
| 2025-01-28 | Sale | Hoffman Allison C | General Counsel & Secretary | 6,235 0.0105% | $28.50 | $177,698 | -3.43% | |
| 2025-01-27 | Sale | Indig Chaim | Chief Executive Officer | 26,248 0.0461% | $27.48 | $721,198 | +5.49% | |
| 2025-01-27 | Sale | Roberts Evan | Chief Operating Officer | 10,716 0.0188% | $27.48 | $294,436 | +5.49% | |
| 2025-01-27 | Sale | Linetsky David | SVP, Life Sciences | 11,685 0.0205% | $27.48 | $321,060 | +5.49% | |
| 2025-01-27 | Sale | Hoffman Allison C | General Counsel & Secretary | 6,556 0.0115% | $27.48 | $180,135 | +5.49% | |
| 2025-01-27 | Sale | Gandhi Balaji | Chief Financial Officer | 4,813 0.0085% | $27.48 | $132,244 | +5.49% | |
| 2025-01-27 | Sale | VanDuyn Amy Beth | SVP, Human Resources | 3,475 0.0061% | $27.48 | $95,480 | +5.49% |
Total: 313
*Gray background shows transactions not older than one year
PHR Institutional Investors: Active Positions
| Increased Positions | 96 | +44.86% | 5M | +8.02% |
| Decreased Positions | 92 | -42.99% | 5M | -8.85% |
| New Positions | 28 | New | 854,163 | New |
| Sold Out Positions | 28 | Sold Out | 2M | Sold Out |
| Total Postitions | 218 | +1.87% | 57M | -0.83% |
PHR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $163,293.00 | 10.61% | 6.15M | -544,669 | -8.13% | 2024-12-31 |
| Brown Advisory Inc | $148,480.00 | 9.65% | 5.59M | -91,534 | -1.61% | 2024-12-31 |
| Blackrock, Inc. | $140,036.00 | 9.1% | 5.28M | +35,872 | +0.69% | 2024-12-31 |
| Vanguard Group Inc | $128,005.00 | 8.32% | 4.82M | +61,048 | +1.28% | 2024-12-31 |
| Greenhouse Funds Lllp | $76,273.00 | 4.96% | 2.87M | +626,579 | +27.88% | 2024-12-31 |
| Capital International Investors | $68,820.00 | 4.47% | 2.59M | 0 | 0% | 2024-12-31 |
| Champlain Investment Partners, Llc | $65,186.00 | 4.24% | 2.46M | -47,688 | -1.91% | 2024-12-31 |
| Rock Springs Capital Management Lp | $54,142.00 | 3.52% | 2.04M | -242,500 | -10.62% | 2024-12-31 |
| Credit Suisse Ag/ | $46,997.00 | 3.05% | 1.77M | -7,464 | -0.42% | 2024-03-31 |
| Franklin Resources Inc | $40,065.00 | 2.6% | 1.51M | +11,986 | +0.8% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.